{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T02:34:34Z","timestamp":1794710074938,"version":"4.9.1"},"reference-count":112,"publisher":"Oxford University Press (OUP)","issue":"Supplement_4","license":[{"start":{"date-parts":[[2020,10,14]],"date-time":"2020-10-14T00:00:00Z","timestamp":1602633600000},"content-version":"vor","delay-in-days":13,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>There have been major advances in the management of axial spondyloarthritis (axSpA) with the introduction of effective biologic agents targeting TNF and IL-17A. Clinicians now have more choice but, despite treatment recommendations, are still faced with significant uncertainty when deciding on the optimal treatment strategy for an individual patient in clinical practice. Management of axSpA typically requires both non-pharmacological and pharmacological interventions. NSAIDs remain the first line drug therapies for axSpA with proven efficacy for symptomatic management but uncertainty remains regarding their optimal long-term use relating to radiographic progression and safety in axSpA. To-date there are no head-to-head trials of biologics in axSpA. Clinicians need to consider other factors, including extra-articular manifestations, comorbidities, safety and radiographic progression when deciding on which biologic to recommend for an individual patient. This article will explore the evidence relating to these factors and highlight areas of unmet need.<\/jats:p>","DOI":"10.1093\/rheumatology\/keaa435","type":"journal-article","created":{"date-parts":[[2020,7,3]],"date-time":"2020-07-03T19:27:04Z","timestamp":1593804424000},"page":"iv79-iv89","source":"Crossref","is-referenced-by-count":65,"title":["Treatment strategies in axial spondyloarthritis: what, when and how?"],"prefix":"10.1093","volume":"59","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4932-7023","authenticated-orcid":false,"given":"George E","family":"Fragoulis","sequence":"first","affiliation":[{"name":"First Department of Propaedeutic Internal Medicine, National and Kapodistrian University of Athens, \u2018Laiko\u2019 General Hospital, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1802-7311","authenticated-orcid":false,"given":"Stefan","family":"Siebert","sequence":"additional","affiliation":[{"name":"Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,10,14]]},"reference":[{"key":"2020112610564099500_keaa435-B1","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1136\/annrheumdis-2016-210770","article-title":"2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis","volume":"76","author":"van der Heijde","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2020112610564099500_keaa435-B2","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1002\/art.41042","article-title":"2019 update of the American College of Rheumatology\/Spondylitis Association of America\/Spondyloarthritis Research and Treatment Network Recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis","volume":"71","author":"Ward","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2020112610564099500_keaa435-B3","doi-asserted-by":"crossref","first-page":"e000396","DOI":"10.1136\/rmdopen-2016-000396","article-title":"Efficacy and safety of biological and targeted-synthetic DMARDs: a systematic literature review informing the 2016 update of the ASAS\/EULAR recommendations for the management of axial spondyloarthritis","volume":"3","author":"Sepriano","year":"2017","journal-title":"RMD Open"},{"key":"2020112610564099500_keaa435-B4","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s40744-019-0146-6","article-title":"Non-radiographic axial spondyloarthritis (nr-axSpA): advances in classification, imaging and therapy","volume":"6","author":"Robinson","year":"2019","journal-title":"Rheumatol Ther"},{"key":"2020112610564099500_keaa435-B5","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1136\/annrheumdis-2014-205322","article-title":"Efficacy of TNF\u03b1 blockers in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis: a meta-analysis","volume":"74","author":"Callhoff","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"2020112610564099500_keaa435-B6","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1002\/art.22290","article-title":"Microdamage and altered vascularity at the enthesis-bone interface provides an anatomic explanation for bone involvement in the HLA-B27-associated spondylarthritides and allied disorders","volume":"56","author":"Benjamin","year":"2007","journal-title":"Arthritis Rheum"},{"key":"2020112610564099500_keaa435-B7","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/nrrheum.2017.188","article-title":"Enthesitis: from pathophysiology to treatment","volume":"13","author":"Schett","year":"2017","journal-title":"Nat Rev Rheumatol"},{"key":"2020112610564099500_keaa435-B8","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1136\/bjsports-2018-099943","article-title":"High intensity exercise for 3 months reduces disease activity in axial spondyloarthritis (axSpA): a multicentre randomised trial of 100 patients","volume":"54","author":"Sveaas","year":"2020","journal-title":"Br J Sports Med"},{"key":"2020112610564099500_keaa435-B9","doi-asserted-by":"crossref","first-page":"e000397","DOI":"10.1136\/rmdopen-2016-000397","article-title":"Efficacy and safety of non-pharmacological and non-biological pharmacological treatment: a systematic literature review informing the 2016 update of the ASAS\/EULAR recommendations for the management of axial spondyloarthritis","volume":"3","author":"Regel","year":"2017","journal-title":"RMD Open"},{"key":"2020112610564099500_keaa435-B10","doi-asserted-by":"crossref","first-page":"27","DOI":"10.3906\/sag-1805-291","article-title":"A prospective clinical investigation of the effects of anti-tnf alpha therapy on exerciscapacity in patients with ankylosing spondylitis","volume":"49","author":"\u00c7apkin","year":"2019","journal-title":"Turkish J Med Sci"},{"key":"2020112610564099500_keaa435-B11","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1136\/annrheumdis-2014-206807","article-title":"EULAR recommendations for patient education for people with inflammatory arthritis","volume":"74","author":"Zangi","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"2020112610564099500_keaa435-B12","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1007\/s00296-016-3549-5","article-title":"Benefit of health education by a training nurse in patients with axial and\/or peripheral psoriatic arthritis: a systematic literature review","volume":"36","author":"Candelas","year":"2016","journal-title":"Rheumatol Int"},{"key":"2020112610564099500_keaa435-B13","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1002\/art.33465","article-title":"Baseline radiographic damage, elevated acute-phase reactant levels, and cigarette smoking status predict spinal radiographic progression in early axial spondylarthritis","volume":"64","author":"Poddubnyy","year":"2012","journal-title":"Arthritis Rheum"},{"key":"2020112610564099500_keaa435-B14","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1136\/annrheumdis-2011-200180","article-title":"Smokers in early axial spondyloarthritis have earlier disease onset, more disease activity, inflammation and damage, and poorer function and health-related quality of life: results from the DESIR cohort","volume":"71","author":"Chung","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"2020112610564099500_keaa435-B15","doi-asserted-by":"crossref","first-page":"e000153","DOI":"10.1136\/rmdopen-2015-000153","article-title":"Lifestyle factors may modify the effect of disease activity on radiographic progression in patients with ankylosing spondylitis: a longitudinal analysis","volume":"1","author":"Ramiro","year":"2015","journal-title":"RMD Open"},{"key":"2020112610564099500_keaa435-B16","doi-asserted-by":"crossref","first-page":"607","DOI":"10.3899\/jrheum.150721","article-title":"Nonsteroidal antiinflammatory drugs for axial spondyloarthritis: a cochrane review","volume":"43","author":"Kroon","year":"2016","journal-title":"J Rheumatol"},{"key":"2020112610564099500_keaa435-B17","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1093\/rheumatology\/kew367","article-title":"Efficiency of treatment with non-steroidal anti-inflammatory drugs according to current recommendations in patients with radiographic and non-radiographic axial spondyloarthritis","volume":"56","author":"Baraliakos","year":"2017","journal-title":"Rheumatology"},{"key":"2020112610564099500_keaa435-B18","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1136\/annrheumdis-2012-203201","article-title":"Efficacy and safety of infliximab plus naproxen versus naproxen alone in patients with early, active axial spondyloarthritis: results from the double-blind, placebo-controlled INFAST study, Part 1","volume":"73","author":"Sieper","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"2020112610564099500_keaa435-B19","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1136\/annrheumdis-2013-203460","article-title":"Maintenance of biologic-free remission with naproxen or no treatment in patients with early, active axial spondyloarthritis. Results from a 6-month, randomised, open-label follow-up study, INFAST Part 2","volume":"73","author":"Sieper","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"2020112610564099500_keaa435-B20","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1002\/art.39690","article-title":"Brief report: course of active inflammatory and fatty lesions in patients with early axial spondyloarthritis treated with infliximab plus naproxen as compared to naproxen alone: results from the infliximab as first line therapy in patients with early active axial spondyloarthritis trial","volume":"68","author":"Poddubnyy","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2020112610564099500_keaa435-B21","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1002\/art.39474","article-title":"Brief report: six-week treatment of axial spondyloarthritis patients with an optimal dose of nonsteroidal antiinflammatory drugs: early response to treatment in signal intensity on magnetic resonance imaging of the sacroiliac joints","volume":"68","author":"Varkas","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2020112610564099500_keaa435-B22","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1136\/annrheumdis-2014-206147","article-title":"Ankylosing spondylitis and risk of ischaemic heart disease: a population-based cohort study","volume":"75","author":"Essers","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2020112610564099500_keaa435-B23","doi-asserted-by":"crossref","first-page":"409","DOI":"10.7326\/M14-2470","article-title":"Patients with ankylosing spondylitis have increased cardiovascular and cerebrovascular mortality: a population-based study","volume":"163","author":"Haroon","year":"2015","journal-title":"Ann Intern Med"},{"key":"2020112610564099500_keaa435-B24","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1136\/ard.2011.151191","article-title":"Increased mortality in ankylosing spondylitis is related to disease activity","volume":"70","author":"Bakland","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"2020112610564099500_keaa435-B25","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1002\/art.21054","article-title":"Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial","volume":"52","author":"Wanders","year":"2005","journal-title":"Arthritis Rheum"},{"key":"2020112610564099500_keaa435-B26","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1136\/annrheumdis-2012-201370","article-title":"Continuous NSAID use reverts the effects of inflammationon radiographic progression in patients with ankylosing spondylitis","volume":"71","author":"Kroon","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"2020112610564099500_keaa435-B27","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1136\/annrheumdis-2011-201252","article-title":"Effect of non-steroidal anti-inflammatory drugs on radiographic spinal progression in patients with axial spondyloarthritis: results from the German Spondyloarthritis Inception Cohort","volume":"71","author":"Poddubnyy","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"2020112610564099500_keaa435-B28","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1136\/annrheumdis-2015-207897","article-title":"Effect of continuous versus on-demand treatment of ankylosing spondylitis with diclofenac over 2 years on radiographic progression of the spine: results from a randomised multicentre trial (ENRADAS)","volume":"75","author":"Sieper","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2020112610564099500_keaa435-B29","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1002\/art.41206","article-title":"Effect of therapy on radiographic progression in axial spondyloarthritis: a systematic review and meta-analysis","volume":"72","author":"Karmacharya","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"2020112610564099500_keaa435-B30","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1056\/NEJMoa1505066","article-title":"Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis","volume":"373","author":"Baeten","year":"2015","journal-title":"N Engl J Med"},{"key":"2020112610564099500_keaa435-B31","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1016\/S0140-6736(18)31946-9","article-title":"Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial","volume":"392","author":"van der Heijde","year":"2018","journal-title":"Lancet"},{"key":"2020112610564099500_keaa435-B32","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0140-6736(19)32971-X","article-title":"Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial","volume":"395","author":"Deodhar","year":"2020","journal-title":"Lancet"},{"key":"2020112610564099500_keaa435-B33","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1002\/art.40753","article-title":"Efficacy and safety of ixekizumab in the treatment of radiographic axial spondyloarthritis: sixteen-week results from a phase iii randomized, double-blind, placebo-controlled trial in patients with prior inadequate response to or intolerance of tumor necrosis factor inhibitors","volume":"71","author":"Deodhar","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2020112610564099500_keaa435-B34","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1124\/pr.114.009639","article-title":"Cytokines as therapeutic targets in rheumatoid arthritis and other inflammatory diseases","volume":"67","author":"Siebert","year":"2015","journal-title":"Pharmacol Rev"},{"key":"2020112610564099500_keaa435-B35","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1002\/art.40728","article-title":"Three multicenter, randomized, double-blind, placebo-controlled studies evaluating the efficacy and safety of ustekinumab in axial spondyloarthritis","volume":"71","author":"Deodhar","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2020112610564099500_keaa435-B36","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1136\/annrheumdis-2018-213328","article-title":"Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study","volume":"77","author":"Baeten","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2020112610564099500_keaa435-B37","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1136\/annrheumdis-2018-213654","article-title":"Why did IL-23p19 inhibition fail in AS: a tale of tissues, trials or translation?","volume":"78","author":"Siebert","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"2020112610564099500_keaa435-B38","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1136\/annrheumdis-2019-215210","article-title":"Evidence that tissue resident human enthesis \u03b3\u03b4T-cells can produce IL-17A independently of IL-23R transcript expression","volume":"78","author":"Cuthbert","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"2020112610564099500_keaa435-B39","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.3389\/fimmu.2018.01550","article-title":"The initiation, but not the persistence, of experimental spondyloarthritis is dependent on interleukin-23 signaling","volume":"9","author":"van Tok","year":"2018","journal-title":"Front Immunol"},{"key":"2020112610564099500_keaa435-B40","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1002\/art.40770","article-title":"Interleukin-17A inhibition diminishes inflammation and new bone formation in experimental spondyloarthritis","volume":"71","author":"Tok","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2020112610564099500_keaa435-B41","doi-asserted-by":"crossref","first-page":"iv43","DOI":"10.1093\/rheumatology\/key276","article-title":"JAK-inhibitors. New players in the field of immune-mediated diseases, beyond rheumatoid arthritis","volume":"58","author":"Fragoulis","year":"2019","journal-title":"Rheumatology"},{"key":"2020112610564099500_keaa435-B42","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.1016\/S0140-6736(18)32463-2","article-title":"Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial","volume":"392","author":"van der Heijde","year":"2018","journal-title":"Lancet"},{"key":"2020112610564099500_keaa435-B43","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1016\/S0140-6736(19)32534-6","article-title":"Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2\/3 trial","volume":"394","author":"van der Heijde","year":"2019","journal-title":"Lancet"},{"key":"2020112610564099500_keaa435-B44","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1136\/annrheumdis-2016-210322","article-title":"Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study","volume":"76","author":"van der Heijde","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2020112610564099500_keaa435-B45","first-page":"174","article-title":"Novel therapeutic targets in axial spondyloarthritis. Curr Treatm Opt","volume":"4","author":"Worth","year":"2018","journal-title":"Rheumatol"},{"key":"2020112610564099500_keaa435-B46","doi-asserted-by":"crossref","first-page":"59","DOI":"10.3899\/jrheum.160958","article-title":"Ankylosing spondylitis versus nonradiographic axial spondyloarthritis: comparison of tumor necrosis factor inhibitor effectiveness and effect of HLA-B27 Status. An observational cohort study from the nationwide DANBIO registry","volume":"44","author":"Glintborg","year":"2017","journal-title":"J Rheumatol"},{"key":"2020112610564099500_keaa435-B47","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1093\/rheumatology\/ket433","article-title":"Body weight, gender and response to TNF- blockers in axial spondyloarthritis","volume":"53","author":"Gremese","year":"2014","journal-title":"Rheumatology"},{"key":"2020112610564099500_keaa435-B48","doi-asserted-by":"crossref","first-page":"195","DOI":"10.3899\/jrheum.17666","article-title":"The sex influence on response to tumor necrosis factor-\u03b1 inhibitors and remission in axial spondyloarthritis","volume":"45","author":"Lubrano","year":"2018","journal-title":"J Rheumatol"},{"key":"2020112610564099500_keaa435-B49","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1186\/s13075-017-1372-3","article-title":"Impact of obesity on the response to tumor necrosis factor inhibitors in axial spondyloarthritis","volume":"19","author":"Micheroli","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"2020112610564099500_keaa435-B50","doi-asserted-by":"crossref","first-page":"3096","DOI":"10.1002\/art.38140","article-title":"Tumor necrosis factor \u03b1 inhibition in radiographic and nonradiographic axial spondyloarthritis: results from a large observational cohort","volume":"65","author":"Ciurea","year":"2013","journal-title":"Arthritis Rheum"},{"key":"2020112610564099500_keaa435-B51","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1136\/ard.2003.016386","article-title":"Prediction of a major clinical (BASDAI 50) to tumour necrosis factor \u03b1 blockers in ankylosing spondylitis","volume":"63","author":"Rudwaleit","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"2020112610564099500_keaa435-B52","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1136\/ard.2007.073098","article-title":"MRI in predicting a major clinical response to anti-tumour necrosis factor treatment in ankylosing spondylitis","volume":"67","author":"Rudwaleit","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"2020112610564099500_keaa435-B53","doi-asserted-by":"crossref","first-page":"e000017","DOI":"10.1136\/rmdopen-2014-000017","article-title":"Predictors of response to TNF antagonists in patients with ankylosing spondylitis and psoriatic arthritis: systematic review and meta-analysis","volume":"1","author":"Maneiro","year":"2015","journal-title":"RMD Open"},{"key":"2020112610564099500_keaa435-B54","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1136\/annrheumdis-2012-201766","article-title":"Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1)","volume":"72","author":"Sieper","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"2020112610564099500_keaa435-B55","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1136\/annrheumdis-2019-215386","article-title":"A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-na\u00efve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial","volume":"79","author":"Mease","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2020112610564099500_keaa435-B56","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1016\/S0140-6736(20)30564-X","article-title":"Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial","volume":"395","author":"McInnes","year":"2020","journal-title":"Lancet"},{"key":"2020112610564099500_keaa435-B57","doi-asserted-by":"crossref","first-page":"481","DOI":"10.3899\/jrheum.170224","article-title":"Comparative efficacy of tumor necrosis factor-\u03b1 inhibitors in ankylosing spondylitis: a systematic review and bayesian network metaanalysis","volume":"45","author":"Wang","year":"2018","journal-title":"J Rheumatol"},{"key":"2020112610564099500_keaa435-B58","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1136\/annrheumdis-2016-210931","article-title":"Tumour necrosis factor inhibitor treatment and occurrence of anterior uveitis in ankylosing spondylitis: results from the Swedish biologics register","volume":"76","author":"Lie","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2020112610564099500_keaa435-B59","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1185\/03007995.2014.969368","article-title":"Comparing the risk of developing uveitis in patients initiating anti-tumor necrosis factor therapy for ankylosing spondylitis: an analysis of a large US claims database","volume":"30","author":"Wendling","year":"2014","journal-title":"Curr Med Res Opin"},{"key":"2020112610564099500_keaa435-B60","doi-asserted-by":"crossref","first-page":"153","DOI":"10.3899\/jrheum.180312","article-title":"Reduced occurrence rate of acute anterior uveitis in ankylosing spondylitis treated with golimumab\u2014the GO-EASY study","volume":"46","author":"van Bentum","year":"2019","journal-title":"J Rheumatol"},{"key":"2020112610564099500_keaa435-B61","doi-asserted-by":"crossref","first-page":"e001161","DOI":"10.1136\/rmdopen-2019-001161","article-title":"The impact of certolizumab pegol treatment on the incidence of anterior uveitis flares in patients with axial spondyloarthritis: 48-week interim results from C-VIEW","volume":"6","author":"van der Horst-Bruinsma","year":"2020","journal-title":"RMD Open"},{"key":"2020112610564099500_keaa435-B62","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.ophtha.2012.09.040","article-title":"Secukinumab in the treatment of noninfectious uveitis: results of three randomized","volume":"120","author":"Dick","year":"2013","journal-title":"Ophthalmology"},{"key":"2020112610564099500_keaa435-B63","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1136\/ard.62.1.74","article-title":"Efficacy of etanercept for treatment of Crohn\u2019s related spondyloarthritis but not colitis","volume":"62","author":"Marzo-Ortega","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"2020112610564099500_keaa435-B64","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1111\/apt.14030","article-title":"Systematic review with meta-analysis: comparative efficacy of biologics for induction and maintenance of mucosal healing in Crohn\u2019s disease and ulcerative colitis controlled trials","volume":"45","author":"Cholapranee","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"2020112610564099500_keaa435-B65","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.3748\/wjg.v25.i18.2162","article-title":"Inflammatory bowel diseases and spondyloarthropathies: from pathogenesis to treatment","volume":"25","author":"Fragoulis","year":"2019","journal-title":"World J Gastroenterol"},{"key":"2020112610564099500_keaa435-B66","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1136\/gutjnl-2011-301668","article-title":"Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn\u2019s disease: unexpected results of a randomised, double-blind placebo-controlled trial","volume":"61","author":"Hueber","year":"2012","journal-title":"Gut"},{"key":"2020112610564099500_keaa435-B67","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1038\/ajg.2016.298","article-title":"A randomized, double-blind, placebo-controlled phase 2 study of brodalumab in patients with moderate-to-severe Crohn\u2019s disease","volume":"111","author":"Targan","year":"2016","journal-title":"Am J Gastroenterol"},{"key":"2020112610564099500_keaa435-B68","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1136\/annrheumdis-2018-214273","article-title":"Incidence rates of inflammatory bowel disease in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis treated with secukinumab: a retrospective analysis of pooled data from 21 clinical trials","volume":"78","author":"Schreiber","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"2020112610564099500_keaa435-B69","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s13555-019-00340-3","article-title":"Safety of ixekizumab treatment for up to 5 years in adult patients with moderate-to-severe psoriasis: results from greater than 17,000 patient-years of exposure","volume":"10","author":"Armstrong","year":"2020","journal-title":"Dermatol Ther"},{"key":"2020112610564099500_keaa435-B70","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1056\/NEJMoa1602773","article-title":"Ustekinumab as induction and maintenance therapy for Crohn\u2019s disease","volume":"375","author":"Feagan","year":"2016","journal-title":"N Engl J Med"},{"key":"2020112610564099500_keaa435-B71","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1215739","article-title":"Vedolizumab as induction and maintenance therapy for Crohn\u2019s disease","volume":"369","author":"Sandborn","year":"2013","journal-title":"N Engl J Med"},{"key":"2020112610564099500_keaa435-B72","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1093\/rheumatology\/key267","article-title":"Emergence of severe spondyloarthropathy-related entheseal pathology following successful vedolizumab therapy for inflammatory bowel disease","volume":"58","author":"Dubash","year":"2019","journal-title":"Rheumatology"},{"key":"2020112610564099500_keaa435-B73","doi-asserted-by":"crossref","first-page":"101606","DOI":"10.1016\/j.bpg.2019.03.002","article-title":"Pharmacology, efficacy and safety of JAK inhibitors in Crohn\u2019s disease","volume":"38\u201339","author":"Ma","year":"2019","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"2020112610564099500_keaa435-B74","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1606910","article-title":"Tofacitinib as induction and maintenance therapy for ulcerative colitis","volume":"376","author":"Sandborn","year":"2017","journal-title":"N Engl J Med"},{"key":"2020112610564099500_keaa435-B75","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1146\/annurev-med-051914-021944","article-title":"Therapeutic targeting of IL-17 and IL-23 cytokines in immune-mediated diseases","volume":"67","author":"Fragoulis","year":"2016","journal-title":"Annu Rev Med"},{"key":"2020112610564099500_keaa435-B76","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.semarthrit.2018.03.010","article-title":"High prevalence of hidradenitis suppurativa symptoms in axial spondyloarthritis patients: a possible new extra-articular manifestation","volume":"48","author":"Rondags","year":"2019","journal-title":"Semin Arthritis Rheum"},{"key":"2020112610564099500_keaa435-B77","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1001\/jamadermatol.2019.4590","article-title":"Risk of inflammatory arthritis after a new diagnosis of hidradenitis suppurativa","volume":"156","author":"Schneeweiss","year":"2020","journal-title":"JAMA Dermatol"},{"key":"2020112610564099500_keaa435-B78","doi-asserted-by":"crossref","DOI":"10.1177\/1759720X19895488","article-title":"Hidradenitis suppurativa: infection, autoimmunity, or both?","volume":"11","author":"Constantinou","year":"2019","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"2020112610564099500_keaa435-B79","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1136\/annrheumdis-2013-204055","article-title":"Evolution of radiographic damage in ankylosing spondylitis: a 12 year prospective follow-up of the OASIS study","volume":"74","author":"Ramiro","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"2020112610564099500_keaa435-B80","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1002\/art.23471","article-title":"Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept","volume":"58","author":"van der Heijde","year":"2008","journal-title":"Arthritis Rheum"},{"key":"2020112610564099500_keaa435-B81","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1002\/art.23901","article-title":"Radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitis","volume":"58","author":"van der Heijde","year":"2008","journal-title":"Arthritis Rheum"},{"key":"2020112610564099500_keaa435-B82","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1093\/rheumatology\/kez363","article-title":"The effect of tumour necrosis factor inhibitors on radiographic progression in axial spondyloarthritis: a systematic literature review","volume":"58","author":"Boers","year":"2019","journal-title":"Rheumatology"},{"key":"2020112610564099500_keaa435-B83","doi-asserted-by":"crossref","DOI":"10.1177\/1759720X20906040","article-title":"Biologic therapy and spinal radiographic progression in patients with axial spondyloarthritis: a structured literature review","volume":"12","author":"Baraliakos","year":"2020","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"2020112610564099500_keaa435-B84","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1136\/annrheumdis-2017-211544","article-title":"TNF blockers inhibit spinal radiographic progression in ankylosing spondylitis by reducing disease activity: results from the Swiss Clinical Quality Management cohort","volume":"77","author":"Molnar","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2020112610564099500_keaa435-B85","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1093\/rheumatology\/key375","article-title":"Secukinumab shows sustained efficacy and low structural progression in ankylosing spondylitis: 4-year results from the MEASURE 1 study","volume":"58","author":"Braun","year":"2019","journal-title":"Rheumatology"},{"key":"2020112610564099500_keaa435-B86","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1002\/art.21790","article-title":"Major reduction in spinal inflammation in patients with ankylosing spondylitis after treatment with infliximab: results of a multicenter, randomized, double-blind, placebo-controlled magnetic resonance imaging study","volume":"54","author":"Braun","year":"2006","journal-title":"Arthritis Rheum"},{"key":"2020112610564099500_keaa435-B87","doi-asserted-by":"crossref","first-page":"4005","DOI":"10.1002\/art.23044","article-title":"Adalimumab significantly reduces both spinal and sacroiliac joint inflammation in patients with ankylosing spondylitis: a multicenter, randomized, double-blind, placebo-controlled study","volume":"56","author":"Lambert","year":"2007","journal-title":"Arthritis Rheum"},{"key":"2020112610564099500_keaa435-B88","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1002\/art.21588","article-title":"Outcome of patients with active ankylosing spondylitis after two years of therapy with etanercept: clinical and magnetic resonance imaging data","volume":"53","author":"Baraliakos","year":"2005","journal-title":"Arthritis Rheum"},{"key":"2020112610564099500_keaa435-B89","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1136\/annrheumdis-2015-207544","article-title":"Long-term effects of secukinumab on MRI findings in relation to clinical efficacy in subjects with active ankylosing spondylitis: an observational study","volume":"75","author":"Baraliakos","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2020112610564099500_keaa435-B90","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1093\/rheumatology\/keu388","article-title":"Characteristics associated with the presence and development of extra-articular manifestations in ankylosing spondylitis: 12-year results from OASIS","volume":"54","author":"Essers","year":"2015","journal-title":"Rheumatology"},{"key":"2020112610564099500_keaa435-B91","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1136\/annrheumdis-2015-207596","article-title":"Clinical and MRI responses to etanercept in early non-radiographic axial spondyloarthritis: 48-week results from the EMBARK study","volume":"75","author":"Maksymowych","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2020112610564099500_keaa435-B92","doi-asserted-by":"crossref","first-page":"e000592","DOI":"10.1136\/rmdopen-2017-000592","article-title":"Secukinumab provides sustained improvements in the signs and symptoms of active ankylosing spondylitis with high retention rate: 3-year results from the phase III trial, MEASURE 2","volume":"3","author":"Marzo-Ortega","year":"2017","journal-title":"RMD Open"},{"key":"2020112610564099500_keaa435-B93","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1186\/s13075-014-0481-5","article-title":"Evaluation of the nonsteroidal anti-inflammatory drug-sparing effect of etanercept in axial spondyloarthritis: results of the multicenter, randomized, double-blind, placebo-controlled SPARSE study","volume":"16","author":"Dougados","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"2020112610564099500_keaa435-B94","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1093\/rheumatology\/kes125","article-title":"Continuous efficacy of etanercept in severe and advanced ankylosing spondylitis: results from a 12-week open-label extension of the SPINE study","volume":"51","author":"Dougados","year":"2012","journal-title":"Rheumatology"},{"key":"2020112610564099500_keaa435-B95","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1136\/annrheumdis-2016-209209","article-title":"High disease activity according to the Ankylosing Spondylitis Disease Activity Score is associated with accelerated radiographic spinal progression in patients with early axial spondyloarthritis: results from the GErman SPondyloarthritis Inception Cohort","volume":"75","author":"Poddubnyy","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2020112610564099500_keaa435-B96","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1136\/annrheumdis-2014-205178","article-title":"Higher disease activity leads to more structural damage in the spine in ankylosing spondylitis: 12-year longitudinal data from the OASIS cohort","volume":"73","author":"Ramiro","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"2020112610564099500_keaa435-B97","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1002\/art.40661","article-title":"Impact of tumor necrosis factor inhibitor versus nonsteroidal antiinflammatory drug treatment on radiographic progression in early ankylosing spondylitis: its relationship to inflammation control during treatment","volume":"71","author":"Park","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2020112610564099500_keaa435-B98","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1007\/s40273-018-0675-9","article-title":"Cost effectiveness of secukinumab for the treatment of active ankylosing spondylitis in the UK","volume":"36","author":"Emery","year":"2018","journal-title":"Pharmacoeconomics"},{"key":"2020112610564099500_keaa435-B99","doi-asserted-by":"crossref","first-page":"159","DOI":"10.2147\/CEOR.S192235","article-title":"Cost-effectiveness of secukinumab compared to other biologics in the treatment of ankylosing spondylitis in Finland","volume":"11","author":"Purmonen","year":"2019","journal-title":"Clin Outcomes Res"},{"key":"2020112610564099500_keaa435-B100","first-page":"30362","author":"Gonz\u00e1lez Fern\u00e1ndez","year":"2019"},{"key":"2020112610564099500_keaa435-B101","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1007\/s11926-017-0648-6","article-title":"Treat to target in axial spondyloarthritis: what are the issues?","volume":"19","author":"Danve","year":"2017","journal-title":"Curr Rheumatol Rep"},{"key":"2020112610564099500_keaa435-B102","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1136\/ard.2007.075309","article-title":"Comparison of two different dosages of celecoxib with diclofenac for the treatment of active ankylosing spondylitis: results of a 12-week randomised, double-blind, controlled study","volume":"67","author":"Sieper","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"2020112610564099500_keaa435-B103","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1002\/art.24408","article-title":"Clinical and imaging efficacy of infliximab in HLA-B27-positive patients with magnetic resonance imaging-determined early sacroiliitis","volume":"60","author":"Barkham","year":"2009","journal-title":"Arthritis Rheum"},{"key":"2020112610564099500_keaa435-B104","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1136\/ard.2010.139667","article-title":"Effects of etanercept versus sulfasalazine in early axial spondyloarthritis on active inflammatory lesions as detected by whole-body MRI (ESTHER): a 48-week randomised controlled trial","volume":"70","author":"Song","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"2020112610564099500_keaa435-B105","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1002\/art.23606","article-title":"Efficacy of adalimumab in the treatment of axial spondylarthritis without radiographically defined sacroiliitis: results of a twelve-week randomized, double-blind, placebo-controlled trial followed by an open-label extension up to week fifty-two","volume":"58","author":"Haibel","year":"2008","journal-title":"Arthritis Rheum"},{"key":"2020112610564099500_keaa435-B106","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1002\/art.20852","article-title":"Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT)","volume":"52","author":"van der Heijde","year":"2005","journal-title":"Arthritis Rheum"},{"key":"2020112610564099500_keaa435-B107","doi-asserted-by":"crossref","first-page":"3402","DOI":"10.1002\/art.23969","article-title":"Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial","volume":"58","author":"Inman","year":"2008","journal-title":"Arthritis Rheum"},{"key":"2020112610564099500_keaa435-B108","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1002\/art.21913","article-title":"Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial","volume":"54","author":"van der Heijde","year":"2006","journal-title":"Arthritis Rheum"},{"key":"2020112610564099500_keaa435-B109","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1136\/annrheumdis-2011-200859","article-title":"Suppression of inflammation and effects on new bone formation in ankylosing spondylitis: evidence for a window of opportunity in disease modification","volume":"72","author":"Maksymowych","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"2020112610564099500_keaa435-B110","doi-asserted-by":"crossref","first-page":"e000399","DOI":"10.1136\/rmdopen-2016-000399","article-title":"Fat metaplasia on MRI of the sacroiliac joints increases the propensity for disease progression in the spine of patients with spondyloarthritis","volume":"3","author":"Maksymowych","year":"2017","journal-title":"RMD Open"},{"key":"2020112610564099500_keaa435-B111","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.semarthrit.2015.08.005","article-title":"Inflammatory and fatty lesions in the spine and sacroiliac joints on whole-body MRI in early axial spondyloarthritis\u20143-year data of the ESTHER trial","volume":"45","author":"Song","year":"2016","journal-title":"Semin Arthritis Rheum"},{"key":"2020112610564099500_keaa435-B112","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1002\/acr.21688","article-title":"Do patients with non-radiographic axial spondylarthritis differ from patients with ankylosing spondylitis?","volume":"64","author":"Kiltz","year":"2012","journal-title":"Arthritis Care Res"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/rheumatology\/article-pdf\/59\/Supplement_4\/iv79\/34551493\/keaa435.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/rheumatology\/article-pdf\/59\/Supplement_4\/iv79\/34551493\/keaa435.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,26]],"date-time":"2020-11-26T18:53:20Z","timestamp":1606416800000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/59\/Supplement_4\/iv79\/5923433"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,1]]},"references-count":112,"journal-issue":{"issue":"Supplement_4","published-online":{"date-parts":[[2020,10,14]]},"published-print":{"date-parts":[[2020,10,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keaa435","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,10]]},"published":{"date-parts":[[2020,10,1]]}}}